The science behind Summit’s success, 23andMe’s fate, and more biotech news updates

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Which CEO drank out of my colleague Matt Herper’s glass of water? Read on today to find out!

The biotech behind Summit’s success isn’t done yet

Earlier this month, we got news that Summit Therapeutics’ antibody ivonescimab decisively beat Merck’s blockbuster Keytruda in a head-to-head lung cancer study. Behind Summit’s success is a little-known Chinese biotech called Akeso. It’s the company that actually discovered ivonescimab and that Summit licensed the therapy from.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In